Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03736889 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

StatusRecruiting
PhasePhase 2
SponsorBeiGene
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 29 to 30v19
  2. Study sites revised (29)v18 See this version in full on ClinicalTrials.gov ↗
  3. Site details revised at 5 of 29 sitesv17
  4. Re-verified, no change to tracked fieldsv16
  5. Study sites: 13 to 29v15
Show 13 earlier versionsHide 13 earlier versions
  1. Study sites: 11 to 13v14
  2. Study sites: 12 to 11v13
  3. Study sites: 11 to 12v12
  4. Study sites: 14 to 11v11
  5. Site details revised at 1 of 14 sitesv10
  6. Study sites: 29 to 14v9
  7. Study sites: 1 to 29v8
  8. Enrollment target: 80 to 200 Primary completion date: Dec 2022 to Nov 2026 · Completion date: Dec 2022 to Sep 2027 · Secondary endpoints revised (7) · 1 morev7 Show 4 more changesShow less
    • Primary completion date: Dec 2022 to Nov 2026
    • Completion date: Dec 2022 to Sep 2027
    • Secondary endpoints revised (7)
    • Eligibility criteria shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  9. Primary completion date: Dec 2021 to Dec 2022 Enrollment target: 79 to 80 · Completion date: May 2022 to Dec 2022v6 Show 2 more changesShow less
    • Enrollment target: 79 to 80
    • Completion date: May 2022 to Dec 2022
  10. Re-verified, no change to tracked fieldsv5
  11. Enrollment target: 60 to 79 Eligibility criteria expanded, about 14 words · Secondary endpoints revised (7) · Study title expanded, about 4 wordsv4 Show 3 more changesShow less
    • Eligibility criteria expanded, about 14 words
    • Secondary endpoints revised (7)
    • Study title expanded, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  12. Site contact updatedv3
  13. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
BeiGene
37 trials monitored
See 1 trial at risk
In this Phase 2, Single-Arm, Multi-Center, Open-Label Study, participants with previously treated locally advanced unresectable or metastatic solid tumors with mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) will be treated with anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317).
Trial Details
NCT Number NCT03736889
Lead Sponsor BeiGene
Conditions MSI-H/dMMR Solid Tumors
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov